Jump to content
Powered by

BPI opens office in Brussels

The German Pharmaceutical Industry Association (BPI) strengthens its European policy activities with an office in Brussels.

src=

BPI chairman Dr. Bernd Wegener said that the new BPI office in Brussels will represent the European interests of German location-oriented pharmaceutical companies at European institutions. BPI is the first German pharmaceutical association with an office in Brussels, and is headed by Dr. Alexander Natz, a lawyer who previously worked for the Sträter law firm in Bonn.

Wegener explains that the move was necessary due to the growing number of European guidelines and regulations relating to the pharmaceutical market. Of all the regulations in the German Medicines Act, approximately 90 per cent originated from European regulations. “The regulations for the domestic market are determined by European regulations. And when these European regulations are redefined, it is necessary to get involved at an early stage of the process and at the place where the decisions are made, and that means Brussels,” said the BPI chairman.

In 2006 alone, the EU Commission published 482 guidelines, ordinances and decisions relating to the EC domestic market, which have a direct impact on the management decisions of the pharmaceutical industry. In the same year, 107 new European Agency for the Evaluation of Medical Products (EMEA) guidelines and documents were accepted by the committees. This means that a total of 589 guidelines and documents have been issued or are being prepared concerning pharmaceutical companies.

Website address: https://www.gesundheitsindustrie-bw.de/en/article/press-release/bpi-opens-office-in-brussels